214 related articles for article (PubMed ID: 25895920)
1. Pembrolizumab Shows Promise for NSCLC.
Cancer Discov; 2015 Jun; 5(6):572. PubMed ID: 25895920
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab Outperforms Docetaxel for NSCLC.
Leslie M
Cancer Discov; 2016 Mar; 6(3):223. PubMed ID: 26811324
[No Abstract] [Full Text] [Related]
3. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.
Carbognin L; Pilotto S; Milella M; Vaccaro V; Brunelli M; Caliò A; Cuppone F; Sperduti I; Giannarelli D; Chilosi M; Bronte V; Scarpa A; Bria E; Tortora G
PLoS One; 2015; 10(6):e0130142. PubMed ID: 26086854
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab shows promise in lung cancer.
Cleghorn S
Lancet Respir Med; 2015 Jun; 3(6):429. PubMed ID: 25935769
[No Abstract] [Full Text] [Related]
5. Pembrolizumab for the treatment of non-small cell lung cancer.
Lim SH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Expert Opin Biol Ther; 2016; 16(3):397-406. PubMed ID: 26800463
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab (Keytruda) for first-line treatment of metastatic NSCLC.
Med Lett Drugs Ther; 2017 Jan; 59(1513):22-23. PubMed ID: 28118650
[No Abstract] [Full Text] [Related]
7. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer.
Dang TO; Ogunniyi A; Barbee MS; Drilon A
Expert Rev Anticancer Ther; 2016; 16(1):13-20. PubMed ID: 26588948
[TBL] [Abstract][Full Text] [Related]
8. Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer.
Roach C; Zhang N; Corigliano E; Jansson M; Toland G; Ponto G; Dolled-Filhart M; Emancipator K; Stanforth D; Kulangara K
Appl Immunohistochem Mol Morphol; 2016 Jul; 24(6):392-7. PubMed ID: 27333219
[TBL] [Abstract][Full Text] [Related]
9. Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.
Leventakos K; Mansfield AS
BioDrugs; 2016 Oct; 30(5):397-405. PubMed ID: 27411930
[TBL] [Abstract][Full Text] [Related]
10. PD-1 Blockers.
Wolchok JD
Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab for the treatment of non-small cell lung cancer.
Muller M; Schouten RD; De Gooijer CJ; Baas P
Expert Rev Anticancer Ther; 2017 May; 17(5):399-409. PubMed ID: 28338376
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab for the first-line treatment of non-small cell lung cancer.
Ninomiya K; Hotta K
Expert Opin Biol Ther; 2018 Oct; 18(10):1015-1021. PubMed ID: 30207786
[TBL] [Abstract][Full Text] [Related]
13. First Anti-PD-L1 Drug Approved for NSCLC.
Cancer Discov; 2016 Dec; 6(12):OF1. PubMed ID: 27920140
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab for the treatment of nonsmall cell lung cancer: Current status and future directions.
Qin Q; Li B
J Cancer Res Ther; 2019; 15(4):743-750. PubMed ID: 31436226
[TBL] [Abstract][Full Text] [Related]
15. PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.
Peters S; Kerr KM; Stahel R
Cancer Treat Rev; 2018 Jan; 62():39-49. PubMed ID: 29156447
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab in lung cancer: current evidence and future perspectives.
Palumbo G; Carillio G; Manzo A; Montanino A; Sforza V; Costanzo R; Sandomenico C; Manna C; Luca G; Piccirillo MC; Daniele G; Cecio R; Botti G; Totaro G; Muto P; Picone C; Esposito G; Normanno N; Morabito A
Future Oncol; 2019 Oct; 15(29):3327-3336. PubMed ID: 31432705
[TBL] [Abstract][Full Text] [Related]
17. Clinical Trials of PD-1 and PD-L1 inhibitors in NSCLC.
Clin Adv Hematol Oncol; 2014 Jan; 12(1 Suppl 1):14-6. PubMed ID: 24852398
[No Abstract] [Full Text] [Related]
18. Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer.
Decatris MP; O'Byrne KJ
Future Oncol; 2016 Aug; 12(15):1805-22. PubMed ID: 27267211
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab for Previously Untreated Patients with Advanced Non-small-cell Lung Cancer and Preexisting Interstitial Lung Disease.
Fujita T; Kuroki T; Hayama N; Shiraishi Y; Amano H; Nakamura M; Hirano S; Tabeta H; Nakamura S
Intern Med; 2020 Aug; 59(16):1939-1945. PubMed ID: 32389949
[TBL] [Abstract][Full Text] [Related]
20. Durable Response After 2 Doses of Pembrolizumab in a Patient With Non-Small-Cell Lung Cancer With an Isolated Brain Metastasis.
Uprety D; Arjyal L; Vallatharasu Y; Bista A; Wittchow RJ; Marinier DE
Clin Lung Cancer; 2019 Sep; 20(5):e552-e554. PubMed ID: 31285178
[No Abstract] [Full Text] [Related]
[Next] [New Search]
